zosurabalpin (RG6006) / Roche - LARVOL DELTA

An Overview of the Epidemiology of Multidrug Resistance and Bacterial Resistance Mechanisms: What Solutions Are Available? A Comprehensive Review. (PubMed, Microorganisms) - "This comprehensive review synthesizes global epidemiological data, insights into bacterial resistance mechanisms, and emerging therapeutic solutions, including novel antibiotics such as lasso peptides and macrocyclic peptides (e.g., zosurabalpin), naturally derived compounds (e.g., corallopyronin, clovibactin, chlorotonil A), and targeted inhibitors (e.g., Debio 1453 for Neisseria gonorrhoeae). Addressing the AMR crisis requires coordinated international efforts, accelerated drug discovery, and the integration of innovative non-antibiotic approaches to preserve the efficacy of existing therapies and ensure preparedness against future bacterial threats."

Journal • Review • Infectious Disease • Pneumococcal Infections • Pneumonia

Activity of Zosurabalpin and Comparator Antimicrobial Agents Tested Against Acinetobacter baumannii-calcoaceticus complex (ABC) Isolates Collected Worldwide in 2024. (IDWeek 2025) - No abstract available

Infectious Disease

Antibiotics and non-traditional antimicrobial agents for carbapenem-resistant Acinetobacter baumannii in Phase 1, 2, and 3 clinical trials. (PubMed, Expert Opin Investig Drugs) - "Specifically, 9 antibiotics are in Phase 1 (R-327, xeruborbactam/QPX-7728, upleganan/SPR-206, MRX-8, QPX-9003, zifanocycline/KBP-7072, apramycin/EBL-1003, zosurabalpin/RG-6006, and ANT-3310), two in Phase 2 (BV-100, OMN-6), and two in Phase 3 (zidebactam/WCK-5222, funobactam/XNW-4107) clinical trials...In particular, two monoclonal antibodies (TRL-1068, CMTX-101), a phage therapy (Phagebank), an immune-modulating agent (recombinant human plasma gelsolin/Rhu-pGSN), a microbiome-modulating agent (SER-155), and an engineered cationic antibiotic peptide (PLG-0206). Several agents with promising characteristics against CRAB infections are in clinical development (Phases 1, 2, and 3). The urgent need for therapeutic options against CRAB infections necessitates optimizing efforts and time for introducing successfully studied agents into clinical practice."

Journal • Review • Infectious Disease • GSN

Drug-resistant Acinetobacter baumannii: mortality, emerging treatments, and future pharmacological targets for a WHO priority pathogen. (PubMed, Clin Microbiol Rev) - "In addition, we discuss emerging druggable targets and the inherent challenges in their development, offering strategic insights into next-generation therapeutic programs. A deep profound understanding of the pathogen's molecular defenses is essential to guide the design of innovative therapies aimed at mitigating the escalating threat posed by A. baumannii."

Journal • Review • Infectious Disease

Targeting Lipopolysaccharides in Gram-negative Sepsis: Therapeutic Advances and Challenges. (PubMed, J Drug Target) - "Key strategies include antibiotics disrupting LPS biosynthesis and transport (e.g., zosurabalpin, darobactin), monoclonal and bispecific antibodies, extracorporeal endotoxin removal devices, and novel agents like LpxC inhibitors and nanotechnology-based platforms...Addressing scalability, regulatory hurdles, and cost-effectiveness will be critical to integrating LPS-targeted therapies into standard sepsis care. This review outlines a translational roadmap to harness these innovations and improve outcomes in Gram-negative sepsis."

Journal • Review • Infectious Disease • Inflammation • Septic Shock

Carbapenem Resistance in Acinetobacter baumannii: Mechanisms, Therapeutics, and Innovations. (PubMed, Microorganisms) - "Emerging treatment strategies are discussed, such as the use of new beta-lactam-beta-lactamase inhibitor combinations (e.g., sulbactam-durlobactam), siderophore cephalosporins, next-generation polymyxins, as well as novel agents like zosurabalpin and rifabutin (BV100). Together, these innovations represent a multifaceted strategy to overcome CRAB infections, yet their successful implementation requires further clinical validation and coordinated surveillance efforts. This analysis highlights the urgent need for continued investment in innovative treatments and effective resistance monitoring to limit the spread of CRAB and protect the effectiveness of last-line antibiotics."

Journal • Review • Critical care • Infectious Disease

Zosurabalpin, a novel antibiotic targeting lipopolysaccharide transport (ASM Microbe 2025) - "There is no abstract associated with this presentation."

Zosurabalpin: an antibiotic with a new mechanism of action against carbapenem-resistant Acinetobacter baumannii. (PubMed, Infez Med) - "With rising resistance and limited effective treatments, zosurabalpin offers a new, targeted therapeutic approach. Continued clinical development could help close a critical gap in the management of multidrug-resistant Acinetobacter baumannii."

Journal • Review • Infectious Disease

In silico analysis of zosurabalpin-LptB2FG binding in Acinetobacter spp., Klebsiella pneumoniae, and Shigella flexneri: mechanisms underlying its differential efficacy. (PubMed, In Silico Pharmacol) - "These findings underscore the need for tailored zosurabalpin derivatives to enhance efficacy against a broader spectrum of Gram-negative bacteria. The online version contains supplementary material available at 10.1007/s40203-025-00343-3."

Journal • Infectious Disease • Pneumonia

In vitro activity of zosurabalpin against carbapenem-resistant-A. baumannii (CRAB) clinical isolates from diverse origins (ESCMID Global 2025) - No abstract available

Late-breaking abstract • Preclinical

Preliminary zosurabalpin (5µg) disk diffusion quality control ranges using clinical and laboratory standards institute M23 criteria (ESCMID Global 2025) - No abstract available

Clinical

Antibacterial effect of zosurabalpin using simulated human doses against carbapenem resistant Acinetobacter baumannii studied in an in vitro model of infection (ESCMID Global 2025) - No abstract available

Preclinical • Infectious Disease

Antimicrobial activity of zosurabalpin against a diverse collection of aerobic and anaerobic bacterial and yeast isolates (ESCMID Global 2025) - No abstract available

Assessment of zosurabalpin activity in combination with other antibiotics (ESCMID Global 2025) - No abstract available

Combination therapy

Effect of zosurabalpin, a pathogen-focused antibiotic, on the gut microbiome of healthy participants (ESCMID Global 2025) - No abstract available

Clinical

Determination of optimal disk diffusion mass for zosurabalpin (ESCMID Global 2025) - No abstract available

Acinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline. (PubMed, Microorganisms) - "Furthermore, many older agents, such as polymyxin and colistin, have limited lung penetration and are associated with significant toxicities. In order to place these newer molecules in context and to help clinicians appreciate the emerging potential drug development pipeline, we describe the in vitro activity, mechanisms of action, and clinical trial data not only for the commercially now available alternatives, such as cefiderocol and sulbactam-durlobactam, but also review these topics for molecules undergoing phase II and III clinical trials. Specifically, we discuss and analyze data related to four novel drugs from ABC: BV-100, cefepime-zidebactam, zosurabalpin, and OMN6."

Journal • Review • Infectious Disease • Pneumonia • Respiratory Diseases • Septic Shock

Potentially effective antimicrobial treatment for pneumonia caused by isolates of carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii complex species: what can we expect in the future? (PubMed, Expert Rev Anti Infect Ther) - "Doubling the routine intravenous maintenance dosages of conventional tigecycline (100 mg every 12 h) and minocycline (200 mg every 12 h) might be recommended for the effective treatment of pneumonia caused by CR/XDR-Abc. Nebulized polymyxin E, novel parenteral rifabutin BV100, and new polymyxin derivatives (SPR206, MRX-8, and QPX9003) could be considered supplementary combination options with other antibiotic classes. Regarding other novel antibiotics, the potency of sulbactam-durlobactam (1 g/1 g infused over 3 h every 6 h intravenously) combined with imipenem-cilastatin, and the β-lactamase inhibitor xeruborbactam, is promising. Continuous infusion of full-dose cefiderocol is likely an effective treatment regimen for CR/XDR-Abc pneumonia. Zosurabalpin exhibits potent anti-CR/XDR-Abc activity in vitro, but its practical use in clinical therapy remains to be evaluated. The clinical application of antimicrobial peptides and bacteriophages requires validation."

Journal • Review • Infectious Disease • Pneumonia • Respiratory Diseases

Zosurabalpin like petrichor: A novel antibiotic class with unprecedented target towards Acinetobacter baumannii. (PubMed, Sci Bull (Beijing)) - No abstract available

Journal

Zosurabalpin: a novel tethered macrocyclic peptide antibiotic that kills carbapenem-resistant Acinetobacter baumannii. (PubMed, MedComm (2020)) - No abstract available

Journal

Unveiling the Secrets of Acinetobacter baumannii: Resistance, Current Treatments, and Future Innovations. (PubMed, Int J Mol Sci) - "Among the most promising alternatives under investigation are the combination sulbactam/durlobactam, cefepime/zidebactam, imipenem/funobactam, xeruborbactam, and the newest molecules such as novel polymyxins or zosurabalpin. Furthermore, the potential of phage therapy, as well as deep learning and artificial intelligence, offer a complementary approach that could be particularly useful in cases where traditional strategies fail. The fight against A. baumannii is not confined to the microcosm of microbiological research or hospital wards; instead, it is a broader public health dilemma that demands a coordinated, global response."

Journal • Review • Infectious Disease

Assessment of zosurabalpin activity in combination with other antibiotics (ECCMID 2024) - No abstract available

Combination therapy

MIC distributions and activity of the novel anti-Acinetobacter agent zosurabalpin (RG6006) (ECCMID 2024) - No abstract available

Target identification and mode of action studies of zosurabalpin (ECCMID 2024) - No abstract available

Pharmacokinetics and safety in ICU patients and healthy participants following single dose administration of zosurabalpin (RG6006), a novel pathogen-specific antibiotic for the treatment of serious Acinetobacter infections (ECCMID 2024) - No abstract available

Clinical • PK/PD data • Infectious Disease